CONZIP Drug Patent Profile

When do Conzip patents expire, and what generic alternatives are available?

Conzip is a drug marketed by Cipher Pharms Inc and is included in one NDA.

The generic ingredient in CONZIP is tramadol hydrochloride. There are thirty-six drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the tramadol hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Conzip

A generic version of CONZIP was approved as tramadol hydrochloride by SUN PHARM INDS INC on June 19^th, 2002.

Summary for CONZIP

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for CONZIP

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cipher Pharms Inc	CONZIP	tramadol hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022370-001	May 7, 2010		RX	Yes	Yes
Cipher Pharms Inc	CONZIP	tramadol hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022370-003	May 7, 2010		RX	Yes	No
Cipher Pharms Inc	CONZIP	tramadol hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022370-004	Aug 1, 2011		DISCN	Yes	No
Cipher Pharms Inc	CONZIP	tramadol hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022370-002	May 7, 2010		RX	Yes	No

International Patents for CONZIP

See the table below for patents covering CONZIP around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2004110410
Australia	2002337967	EXTENDED RELEASE COMPOSITION CONTAINING TRAMADOL
Canada	2495463	COMPOSITION A LIBERATION MODIFIEE CONTENANT DU TRAMADOL (EXTENDED RELEASE COMPOSITION CONTAINING TRAMADOL)

Supplementary Protection Certificates for CONZIP

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2488169	C202330042	Spain		PRODUCT NAME: COCRISTAL DE TRAMADOL, OPCIONALMENTE EN FORMA DE UNA SAL FISIOLOGICAMENTE ACEPTABLE, Y CELECOXIB; NATIONAL AUTHORISATION NUMBER: 89051; DATE OF AUTHORISATION: 20230925; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 89051; DATE OF FIRST AUTHORISATION IN EEA: 20230925
0566709	SPC/GB04/012	United Kingdom		PRODUCT NAME: TRAMADOL HYDROCHLORIDE, PARACETAMOL; REGISTERED: FR NL 25970 20020405; UK PL 00242/0384 20030925
0566709	C300152	Netherlands		PRODUCT NAME: TRAMADOLI HYDROCHLORIDUM EN PARACETAMOLUM; NAT. REGISTRATION NO/DATE: RVG 28113 20030115; FIRST REGISTRATION: 359 228-3 2002050405

Investment Scenario, Market Dynamics, and Financial Trajectory for Conzip (tramadol hydrochloride)

Last updated: February 3, 2026

---

Executive Summary

Conzip, a controlled-release formulation of tramadol hydrochloride, is primarily used for moderate to severe pain management. Its investment landscape involves product lifecycle stages, regulatory environment considerations, competitive positioning, and market demand driven by pain management trends. Analyzing patent status, market size, growth forecasts, and regulatory shifts provides insights into potential financial trajectories. This report evaluates current market dynamics, forecasts future performance, and presents investment considerations with a focus on Conzip’s unique positioning.

---

1. Product Overview

Attribute	Details
Submitted by	Depomed, Inc. (now part of Allergan; acquired by AbbVie)
Approval Date	2009 (FDA approval)
Active Ingredient	Tramadol hydrochloride
Formulation	Extended-release capsule (Conzip)
Indications	Management of moderate to severe pain

Note: Conzip’s formulation offers improved compliance and reduced dosing frequency, giving it a competitive edge over immediate-release tramadol formulations.

---

2. Patent and Regulatory Landscape

Factor	Details & Implications
Patent Status	Patent expiration in the U.S. occurred in 2021, opening pathways for generic entrants (per FDA listings) [1].
Regulatory Exclusivity	Orphan exclusivity or market protection did not extend beyond original patents, now expired.
Implication	Increased generic competition likely reduces price points and margins but expands total market volume potential.

3. Market Size and Demand Dynamics

Market Segment	Data/Trends
Global Pain Management Market	Estimated at USD 69.8 billion in 2022; projected CAGR of 4.3% (2023–2030) [2].
Conzip Market Share	Estimated at USD 50–100 million pre-generic entry (2020); potential to grow with new indications and off-label uses.
Target Population	U.S. adults with moderate-to-severe pain; estimates at approximately 50 million patients annually in the U.S. [3].
Key Drivers	Aging populations, rising chronic pain conditions, shift towards formulations reducing dosing frequency.

4. Market Dynamics and Competitive Landscape

Key Factors	Details
Generic Competition	Post-patent expiry, multiple generics entered, leading to significant price erosion [1].
Pharmaceutical Innovation	Modified-release formulations face pressure from abuse-deterrent technologies and new NSAID or opioid alternatives.
Regulatory Shift	Increasing regulation on opioids due to abuse potential; impacts prescribing patterns.
Reimbursement Policies	Variations in insurance coverage influence patient access; CMS updates impact outpatient prescribing.

5. Financial Trajectory Analysis

Parameter	Current Status & Forecast
Revenue (2020-2022)	Estimated at USD 70–90 million annually pre-generic erosion.
Price Trends	30-50% price reduction expected post-generic entry (based on historical opioid product declines).
Margins	Initially high (~70%), declined to estimated 30-40% margin due to price erosion.
Forecasted Revenue (2023–2027)	Stabilization with a gradual decline; potential for niche markets or new formulations to offset erosion.
Market Growth Opportunity	If new formulations or indications emerge, revenues could recover or expand; e.g., combination products or abuse-deterrent versions.

Scenario Comparison	Base Case	Optimistic	Pessimistic
Revenue in 2025	USD 50 million	USD 70 million	USD 30 million
Profit Margin	35%	40%	20%
Market Share Post-Generic	10–20%	20–30%	<10%

---

6. Investment Considerations

What is the current valuation opportunity?

• The patent expiry and subsequent generics have reduced revenue potential, yet niche markets and new formulations could sustain interest.
• Companies innovating in abuse-deterrent formulations or combination therapies may unlock profitable avenues.

What are key risks?

• Regulatory Risks: Increased scrutiny of opioids propagates stricter prescribing guidelines.
• Market Risks: Price erosion, market saturation, and substitution by alternative pain therapies.
• Competitive Risks: Entry of aggressive generics, biosimilars, or new non-opioid analgesics.

What are potential strategic moves?

Strategy	Rationale
Development of Abuse-Deterrent Formulations	Address regulatory concerns and position as premium product.
Expansion into New Indications	Chronic pain, cancer pain, or off-label uses.
Partnerships and Licensing	Collaborate with biotech for novel delivery systems or formulations.
Geographic Expansion	Focus on emerging markets with less intense competition.

7. Comparison with Competing Products

Product	Formulation	Indication	Patent Status	Market Share	Pricing	Notes
Tramadol ER (generic)	Extended-release	Pain	Patents expired in 2021	High (dominates market)	Low	Competitive pricing due to generics
Ultram ER	Extended-release	Pain	Patents expired	20–30% of tramadol market	Moderate	Replaced by generics
Other opioids	Immediate and extended-release	Pain	Varies	Significant	Variable	Regulatory pressure affecting growth
New formulations/alternatives	Abuse-deterrent, combination products	Pain	Pending development	Emerging	Premium	Potential disruptors

---

8. Future Market and Financial Outlook

Forecast Parameter	2023–2027 (Estimates)
Global Pain Market CAGR	4.3%
Conzip Revenue Trends	Decline post-2022, stabilization via niche markets or reformulations.
Potential Resurgence	Through adoption in specific patient populations or new delivery systems.
Overall Investment Outlook	Caution advised; opportunistic expansion if formulations innovate or indications broaden.

---

Key Related Policy and Industry Trends

Policy Shift	Implication
Opioid Prescribing Regulations	Reduced prescriptions, necessitating differentiation or repositioning.
FDA Abuse-Deterrent Standards	Incentivize formulation innovation.
Reimbursement Trends	Favoring non-opioid, non-structured pain treatments.

---

Conclusion

The financial prospects of Conzip depend heavily on post-patent market dynamics, regulatory policies, and innovation strategies. The loss of patent exclusivity has precipitated a significant decline in revenues, typical of many branded formulations facing generic competition. However, opportunities remain in niche markets, reformulation efforts, and expansion into new indications.

Investors should weigh the high risks associated with declining revenues against the potential for value creation through strategic innovation and market repositioning. Long-term viability requires active engagement in reformulation, niche marketing, and adaptation to regulatory shifts.

---

Key Takeaways

• Patent expiry in 2021 significantly impacted revenues, leading to increased generic competition.
• The global pain market offers growth opportunities but is increasingly competitive, especially for opioids.
• Innovation in abuse-deterrent formulations or new delivery mechanisms is essential for future profitability.
• Regulatory challenges and shifting prescribing patterns pose ongoing risks.
• A diversification strategy, including expansion into niche markets and new indications, can mitigate revenue erosion.

---

FAQs

Q1: How does patent expiration influence Conzip’s market viability?
A: Patent expiration opens the market to generics, drastically reducing prices and margins but increasing volume potential. Sustained viability depends on differentiation through formulations or new indications.

Q2: What regulatory challenges impact Conzip’s future?
A: Regulatory authorities have increased scrutiny on opioid products due to abuse concerns, leading to stricter prescribing guidelines, which could limit market size.

Q3: Can reformulation mitigate revenue decline?
A: Yes. Developing abuse-deterrent formulations or combining Conzip with other agents can create premium products with renewed market demand.

Q4: What is the potential of Conzip in emerging markets?
A: Less saturated with generics and regulatory restrictions, emerging markets may present growth opportunities through strategic entry and distribution.

Q5: How does Conzip compare to other pain management drugs?
A: Its extended-release design offers advantages in compliance, but it faces stiff competition from other formulations and non-opioid alternatives, especially as regulatory policies evolve.

---

References

[1] U.S. Food and Drug Administration (FDA), Orange Book listings, 2022.
[2] MarketsandMarkets, Pain Management Market Report, 2022.
[3] CDC, Chronic Pain Epidemiology, 2021.